SCHEMBL20652182

SCHEMBL20652182

CS(=O)(=O)OCC(F)CNc1nc(Cl)ncc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17B O94768 1/20 0.40
STK17A Q9UEE5 1/20 0.40
TLR9 Q9NR96 2/20 0.33
MEN1 O00255 1/20 0.33
AGTR1 P30556 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
ALDH1A1 P00352 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
NPC1 O15118 1/20 0.32
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
XBP1 P17861 1/20 0.32
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
HSD17B10 Q99714 1/20 0.32
S100A9 P06702 1/20 0.30
LRRK2 Q5S007 1/20 0.30
CCR4 P51679 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20652181 0.80 STK17B (0.39) STK17BSTK17AALDH1A1L3MBTL1
SCHEMBL20640564 0.76 ALDH1A1 (0.41) STK17BSTK17AKMT2AALDH1A1L3MBTL1
SCHEMBL20652230 0.75 STK17A (0.42) STK17BSTK17AMEN1KMT2AALDH1A1
SCHEMBL1935123 0.75 ALDH1A1 (0.41) STK17BSTK17AKMT2AALDH1A1L3MBTL1
SCHEMBL20640658 0.74 STK17B (0.34) STK17BSTK17ATLR9MEN1AGTR1
SCHEMBL2061199 0.74 STK17B (0.40) STK17BSTK17ATLR9ALDH1A1L3MBTL1
SCHEMBL1937307 0.72 ESR1 (0.49) STK17BSTK17ARAB9AALDH1A1L3MBTL1
SCHEMBL20640625 0.71 GLP1R (0.36) STK17BSTK17AS100A9LRRK2
SCHEMBL20640650 0.71 STK17B (0.34) STK17BSTK17A
SCHEMBL20640705 0.69 CRHR1 (0.34) STK17BSTK17ATLR9ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200392158-A1 INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-12-17 US disclosed
US-20200392158-A1 INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-12-17 US disclosed
CN-110891954-A Inhibitors of leucine-rich repeat kinase 2 葛兰素史密斯克莱知识产权发展有限公司 2020-03-17 CN disclosed
WO-2019012093-A1 INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392158-A1 INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 LRRK2, PARK7, PINK1 STK17B 204/4885STK17A 264/4885TLR9 3998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.